Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease

Trial Profile

Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Piromelatine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Acronyms ReCOGNITION
  • Sponsors NEURIM Pharmaceuticals
  • Most Recent Events

    • 28 Sep 2016 According to Neurim media release, first patients have been enrolled in this study.
    • 28 Jun 2016 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
    • 28 Jun 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top